Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-/-)/AT1A(-/-) double knock out mice (Q45385785)

14 December 2017

title

Stimulation of the AT2 receptor reduced atherogenesis in ApoE(-/-)/AT1A(-/-) double knock out mice (English)

1 reference

14 December 2017

7

Georg Nickenig

1 reference

14 December 2017

1

Vedat Tiyerili

1 reference

14 December 2017

3

Ulrich M Becher

1 reference

14 December 2017

8

Sven Wassmann

1 reference

14 December 2017

author name string

Cornelius F H Mueller

2

1 reference

14 December 2017

Thomas Czech

4

1 reference

14 December 2017

Martin van Eickels

5

1 reference

14 December 2017

Andreas Daiber

6

1 reference

14 December 2017

publication date

22 December 2011

1 reference

Journal of Molecular and Cellular Cardiology

14 December 2017

published in

1 reference

14 December 2017

volume

52

1 reference

14 December 2017

issue

3

1 reference

14 December 2017

page(s)

630-637

1 reference

The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Inflammation and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Central role of the AT(1)-receptor in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Atherosclerosis — An Inflammatory Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Estrogen modulates AT1 receptor gene expression in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Increased NADH-Oxidase–Mediated Superoxide Production in the Early Stages of Atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Role of bradykinin in the vasodilator effects of losartan and enalapril in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

The role of the renin-angiotensin system in the development of cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

PPARgamma and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Enhanced osmotic responsiveness in angiotensin AT1a receptor deficient mice: evidence for a role for AT1b receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Functional evidence that in the cardiovascular system AT1 angiotensin II receptors are AT1B prejunctionally and AT1A postjunctionally

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

A major role for AT1b receptor in mouse mesenteric resistance vessels and its distribution in heart and neuroendocrine tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Angiotensin II-induced vascular dysfunction is mediated by the AT1A receptor in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Angiotensin II stimulates superoxide production via both angiotensin AT1A and AT1B receptors in mouse aorta and heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

AT1b receptor predominantly mediates contractions in major mouse blood vessels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Angiotensin AT1B receptor mediates calcium signaling in vascular smooth muscle cells of AT1A receptor-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

The angiotensin type 2 receptor: variations on an enigmatic theme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Angiotensin II, type 2 receptor is not involved in the angiotensin II-mediated pro-atherogenic process in ApoE-/- mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Role of angiotensin II-regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Angiotensin II Type 2 Receptor Deficiency Exacerbates Heart Failure and Reduces Survival After Acute Myocardial Infarction in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

Telmisartan, ramipril, or both in patients at high risk for vascular events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2011.12.007

10.1016/J.YJMCC.2011.12.007

7 January 2021

Identifiers

DOI

1 reference

14 December 2017

1 reference